J&J Beats $258M Risperdal Verdict In Split La. High Court

Law360, New York (January 28, 2014, 8:11 PM EST) -- A split Louisiana Supreme Court on Tuesday nixed a $258 million jury award against Johnson & Johnson unit Janssen Pharmaceuticals Inc. over its marketing of the antipsychotic drug Risperdal, finding that the state failed to prove the companies defrauded Louisiana's Medicaid program.

In a significant win for J&J, the state high court ruled 4-3 to reverse an August 2012 appeals court decision that preserved a $258 million jury verdict against Janssen secured by state Attorney General James D. "Buddy" Caldwell. The nearly decadelong dispute stems from allegations that Janssen downplayed Risperdal's links to diabetes and touted its safety in an aggressive...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!